Login
Super Investors Rosalind Advisors, Inc.
RA

Rosalind Advisors, Inc.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$312M
Positions
46
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (12 quarters reported)

$312M $107M
Q4 23 Q3 24 Q2 25 Q1 26 Q3 26

$121M in Q4 2023 → $312M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Delcath Systems, Inc. 16.9% Unchanged 3,300,389 $52.7M
Verastem Inc 10.9% Added 6.3% 4,236,509 $34.1M
FP Fennec Pharmaceuticals Inc 10.9% Unchanged 3,188,001 $34M
Xeris Biopharma Holdings Inc 7.9% Trimmed 11% 2,582,647 $24.7M
Cybin Inc 5.5% Trimmed 29% 1,387,969 $17.1M
Savara Inc 5.3% Unchanged 3,178,121 $16.4M
Replimune Group Inc 4.2% New 1,000,000 $13.2M
Vor Biopharma Inc 3.7% Trimmed 6.1% 609,199 $11.6M
Mediwound Ltd 3.3% Unchanged 749,054 $10.3M
X4 Pharmaceuticals Inc 3.0% Unchanged 3,214,766 $9.32M
Aquestive Therapeutics Inc 3.0% Added 700% 2,000,000 $9.26M
Vaxcyte Inc 2.7% Trimmed 25% 149,361 $8.5M
Protara Therapeutics Inc 2.3% New 2,400,000 $7.32M
Myomo Inc 2.0% Added 7.7% 3,917,886 $6.11M
Biocryst Pharmaceuticals Inc 1.9% Unchanged 721,504 $6.01M
Rocket Pharmaceuticals Inc 1.9% New 2,200,000 $5.79M
Pepgen Inc 1.6% Added 471% 2,000,000 $4.84M
Profound Medical Corp 1.5% Unchanged 828,118 $4.8M
Talphera Inc 1.5% Trimmed 20% 4,134,144 $4.8M
Neuraxis Inc 1.3% Added 7.9% 548,123 $4.04M
Ovid Therapeutics Inc 0.9% Unchanged 1,107,994 $2.76M
Inspiremd Inc 0.8% Unchanged 3,905,743 $2.62M
Acumen Pharmaceuticals Inc 0.8% New 1,100,000 $2.44M
Eyepoint Inc 0.7% Trimmed 30% 695,977 $2.28M
AS Abivax Sa 0.7% Unchanged 20,869 $2.07M
Biofrontera Inc 0.6% Added 40% 1,789,288 $1.93M
Femasys Inc 0.5% New 759,213 $1.64M
Atea Pharmaceuticals Inc 0.5% Trimmed 74% 280,061 $1.46M
Cg Oncology Inc 0.5% New 20,000 $1.42M
Spruce Biosciences Inc 0.4% Added 33% 26,517 $1.29M
RB Regentis Biomaterials Ltd 0.4% Unchanged 701,685 $1.27M
Kura Oncology Inc 0.3% Unchanged 100,000 $1.07M
Grace Therapeutics Inc 0.3% New 476,190 $1.02M
Polypid Ltd 0.3% Trimmed 55% 177,011 $933K
SS SPDR Series Trust Put 0.3% Added 78% 250,000 $925K
SS State Str SPDR S&P 500 ETF T Put 0.1% New 100,000 $382K
Verastem Inc Call 0.1% New 293,600 $357K
IQ Invesco Qqq Tr Put 0.1% New 50,000 $258K
Pepgen Inc Call 0.1% New 412,700 $257K
Onkure Therapeutics Inc 0.1% Trimmed 55% 67,506 $184K
Xeris Biopharma Holdings Inc Call 0.1% New 400,000 $160K
Sellas Life Sciences Group Inc Put 0.0% Added 8.8% 618,800 $127K
Bristol-myers Squibb Co Call 0.0% New 20,000 $84.2K
Eyepoint Inc Call 0.0% Added 1295% 701,700 $50K
Corcept Therapeutics Inc Put 0.0% New 10,000 $23.5K
Celldex Therapeutics Inc Put 0.0% New 128,800 —

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Replimune Group Inc New +1,000,000 +$13.2M 4.2%
Aquestive Therapeutics Inc Added +1,750,000 +$8.1M 3.0%
Celldex Therapeutics Inc Exited −200,000 −$7.44M —
Protara Therapeutics Inc New +2,400,000 +$7.32M 2.3%
Cybin Inc Trimmed −568,845 −$6.99M 5.5%
Rocket Pharmaceuticals Inc New +2,200,000 +$5.79M 1.9%
Atea Pharmaceuticals Inc Trimmed −790,489 −$4.12M 0.5%
Pepgen Inc Added +1,650,000 +$3.99M 1.6%
Xeris Biopharma Holdings Inc Trimmed −326,334 −$3.12M 7.9%
Vaxcyte Inc Trimmed −50,639 −$2.88M 2.7%

Showing the 10 largest of 38 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Verastem Inc Added +1,848,034 +$7.06M 5.7%
Cg Oncology Inc Exited −100,000 −$6.77M —
Vaxcyte Inc Trimmed −90,000 −$5.23M 4.3%
VT Viridian Therapeutics Inc Exited −250,401 −$4.9M —
Celldex Therapeutics Inc Trimmed −130,000 −$4.84M 2.8%
FP Fennec Pharmaceuticals Inc Added +279,800 +$3.01M 12.7%
Cybin Inc Added +425,000 +$2.81M 4.8%
AS Abivax Sa New +20,869 +$2.78M 1.0%
Replimune Group Inc Exited −1,275,600 −$2.75M —
Xeris Biopharma Holdings Inc Trimmed −322,719 −$2.56M 8.6%

Showing the 10 largest of 39 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 14, 2026

Company Action Shares changed Value of change % of portfolio
Vaxcyte Inc New +290,000 +$16.9M 6.8%
Replimune Group Inc Exited −1,410,497 −$13.7M —
Astria Therapeutics Inc Exited −1,039,080 −$13.6M —
Cg Oncology Inc Trimmed −200,000 −$13.5M 2.7%
Vor Biopharma Inc New +700,000 +$12.5M 5.0%
Cytokinetics Inc Exited −195,045 −$12.4M —
Celldex Therapeutics Inc New +330,000 +$10.5M 4.2%
Mind Medicine Mindmed Inc Exited −750,000 −$10M —
Biocryst Pharmaceuticals Inc New +923,057 +$8.79M 3.5%
Xeris Biopharma Holdings Inc Added +1,120,000 +$6.5M 7.5%

Showing the 10 largest of 48 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 12, 2026

Company Action Shares changed Value of change % of portfolio
Rezolute Inc Exited −1,807,202 −$17M —
Replimune Group Inc New +1,410,497 +$13.7M 4.8%
Cytokinetics Inc Trimmed −204,955 −$13M 4.4%
Verona Pharma PLC Exited −100,000 −$10.7M —
Fractyl Health Inc Trimmed −4,614,269 −$10.2M 0.3%
Ideaya Biosciences Inc Exited −350,000 −$9.52M —
UN Uniqure Nv Exited −125,000 −$7.3M —
VT Viridian Therapeutics Inc Trimmed −150,000 −$4.67M 4.9%
Atyr Pharma Inc Exited −1,570,200 −$4.47M —
Arrivent Biopharma Inc New +215,871 +$4.34M 1.5%

Showing the 10 largest of 38 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 13, 2025

Company Action Shares changed Value of change % of portfolio
Ocular Therapeutix Inc Trimmed −818,700 −$9.57M 1.6%
Eyepoint Pharmaceuticals Inc New +650,000 +$9.26M 3.2%
Replimune Group Inc Exited −900,000 −$8.36M —
Fractyl Health Inc New +5,000,000 +$7.95M 2.7%
Atyr Pharma Inc New +1,039,080 +$7.56M 2.6%
Urogen Pharma Ltd Exited −542,366 −$7.43M —
UN Uniqure Nv New +125,000 +$7.3M 2.5%
Mediwound Ltd Added +341,993 +$6.16M 4.6%
X4 Pharmaceuticals Inc New +1,544,607 +$5.28M 1.8%
Savara Inc Added +1,345,056 +$4.8M 4.9%

Showing the 10 largest of 43 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Cytokinetics Inc New +400,000 +$13.2M 6.3%
Abeona Therapeutics Inc Exited −1,805,817 −$8.6M —
Rezolute Inc New +1,741,211 +$7.77M 3.7%
Urogen Pharma Ltd Trimmed −407,634 −$5.58M 3.5%
Cg Oncology Inc New +192,974 +$5.02M 2.4%
Nuvation Bio Inc Exited −2,451,500 −$4.31M —
DS Delcath Sys Inc Added +400,000 +$4M 15.6%
Ideaya Biosciences Inc Trimmed −188,868 −$3.97M 5.1%
Verastem Inc Trimmed −600,954 −$2.49M 4.0%
Optinose Inc Exited −256,190 −$2.35M —

Showing the 10 largest of 37 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

Company Action Shares changed Value of change % of portfolio
Ideaya Biosciences Inc New +700,000 +$11.5M 5.6%
Chimerix Inc Exited −3,050,000 −$10.6M —
Verastem Inc Added +1,744,517 +$10.5M 7.8%
VT Viridian Therapeutics Inc New +595,000 +$8.02M 3.9%
Replimune Group Inc Added +590,000 +$5.75M 4.0%
Optinose Inc Trimmed −620,806 −$5.69M 1.1%
Nuvation Bio Inc New +2,451,500 +$4.31M 2.1%
Cassava Sciences Inc Exited −417,400 −$3.65M —
Pharvaris N V New +223,627 +$3.51M 1.7%
Xeris Biopharma Holdings Inc Trimmed −609,009 −$3.34M 6.7%

Showing the 10 largest of 41 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Cormedix Inc Exited −1,475,000 −$11.9M —
Chimerix Inc New +3,050,000 +$10.6M 5.4%
Cybin Inc Exited −1,075,105 −$9.56M —
Urogen Pharma Ltd New +870,000 +$9.27M 4.7%
Savara Inc New +2,654,944 +$8.15M 4.2%
FP Fennec Pharmaceuticals Inc New +1,259,876 +$7.96M 4.1%
Cellectar Biosciences Inc Exited −3,671,550 −$7.86M —
Cybin Inc New +810,918 +$7.15M 3.7%
Optinose Inc New +876,996 +$5.86M 3.0%
Verona Pharma PLC Trimmed −125,000 −$5.81M 3.6%

Showing the 10 largest of 51 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support